253 related articles for article (PubMed ID: 19800368)
41. A novel flavanone derivative inhibits dengue virus fusion and infectivity.
Srivarangkul P; Yuttithamnon W; Suroengrit A; Pankaew S; Hengphasatporn K; Rungrotmongkol T; Phuwapraisirisan P; Ruxrungtham K; Boonyasuppayakorn S
Antiviral Res; 2018 Mar; 151():27-38. PubMed ID: 29360474
[TBL] [Abstract][Full Text] [Related]
42. Progress in the identification of dengue virus entry/fusion inhibitors.
De La Guardia C; Lleonart R
Biomed Res Int; 2014; 2014():825039. PubMed ID: 25157370
[TBL] [Abstract][Full Text] [Related]
43. Interference in dengue virus adsorption and uncoating by carrageenans.
Talarico LB; Damonte EB
Virology; 2007 Jul; 363(2):473-85. PubMed ID: 17337028
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells.
Huerta V; Chinea G; Fleitas N; Sarría M; Sánchez J; Toledo P; Padrón G
Virus Res; 2008 Nov; 137(2):225-34. PubMed ID: 18723056
[TBL] [Abstract][Full Text] [Related]
45. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism.
Diamond MS; Harris E
Virology; 2001 Oct; 289(2):297-311. PubMed ID: 11689052
[TBL] [Abstract][Full Text] [Related]
46. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
Fredericksen BL; Whitt MA
Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
[TBL] [Abstract][Full Text] [Related]
47. A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance.
Watterson D; Robinson J; Chappell KJ; Butler MS; Edwards DJ; Fry SR; Bermingham IM; Cooper MA; Young PR
Sci Rep; 2016 Mar; 6():22791. PubMed ID: 26976324
[TBL] [Abstract][Full Text] [Related]
48. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
Roehrig JT; Bolin RA; Kelly RG
Virology; 1998 Jul; 246(2):317-28. PubMed ID: 9657950
[TBL] [Abstract][Full Text] [Related]
49. How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion.
Chao LH; Jang J; Johnson A; Nguyen A; Gray NS; Yang PL; Harrison SC
Elife; 2018 Jul; 7():. PubMed ID: 29999491
[TBL] [Abstract][Full Text] [Related]
50. A high-throughput assay using dengue-1 virus-like particles for drug discovery.
Qing M; Liu W; Yuan Z; Gu F; Shi PY
Antiviral Res; 2010 May; 86(2):163-71. PubMed ID: 20153777
[TBL] [Abstract][Full Text] [Related]
51. Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors.
Yang JM; Chen YF; Tu YY; Yen KR; Yang YL
PLoS One; 2007 May; 2(5):e428. PubMed ID: 17502914
[TBL] [Abstract][Full Text] [Related]
52. The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion.
Huang CY; Butrapet S; Moss KJ; Childers T; Erb SM; Calvert AE; Silengo SJ; Kinney RM; Blair CD; Roehrig JT
Virology; 2010 Jan; 396(2):305-15. PubMed ID: 19913272
[TBL] [Abstract][Full Text] [Related]
53. The flavivirus precursor membrane-envelope protein complex: structure and maturation.
Li L; Lok SM; Yu IM; Zhang Y; Kuhn RJ; Chen J; Rossmann MG
Science; 2008 Mar; 319(5871):1830-4. PubMed ID: 18369147
[TBL] [Abstract][Full Text] [Related]
54. Targeting a conserved pocket (n-octyl-β-D-glucoside) on the dengue virus envelope protein by small bioactive molecule inhibitors.
Naresh P; Selvaraj A; Shyam Sundar P; Murugesan S; Sathianarayanan S; Namboori P K K; Jubie S
J Biomol Struct Dyn; 2022 Jul; 40(11):4866-4878. PubMed ID: 33345726
[TBL] [Abstract][Full Text] [Related]
55. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection.
Alen MM; Kaptein SJ; De Burghgraeve T; Balzarini J; Neyts J; Schols D
Virology; 2009 Apr; 387(1):67-75. PubMed ID: 19264337
[TBL] [Abstract][Full Text] [Related]
56. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation.
Mondotte JA; Lozach PY; Amara A; Gamarnik AV
J Virol; 2007 Jul; 81(13):7136-48. PubMed ID: 17459925
[TBL] [Abstract][Full Text] [Related]
57. Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus.
Parkinson T; Pryde DC
Future Med Chem; 2010 Jul; 2(7):1181-203. PubMed ID: 21426163
[TBL] [Abstract][Full Text] [Related]
58. In vitro analysis of synthetic peptides in blocking the entry of dengue virus.
John AM; Jittmittraphap A; Chattanadee S; Alwin Prem Anand A; Shenbagarathai R; Leaungwutiwong P
Virus Res; 2019 Jan; 260():142-150. PubMed ID: 30508603
[TBL] [Abstract][Full Text] [Related]
59. Carbohydrate-related inhibitors of dengue virus entry.
Hidari KI; Abe T; Suzuki T
Viruses; 2013 Feb; 5(2):605-18. PubMed ID: 23389466
[TBL] [Abstract][Full Text] [Related]
60. Novel binding between pre-membrane protein and vacuolar ATPase is required for efficient dengue virus secretion.
Duan X; Lu X; Li J; Liu Y
Biochem Biophys Res Commun; 2008 Aug; 373(2):319-24. PubMed ID: 18573235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
